Scilex Holding (SCLX) Research & Development (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Research & Development of $3.2 million for Q1 2026, up 30.7% year-over-year from $2.5 million in Q1 2025, and down 60.7% quarter-over-quarter from $8.2 million in Q4 2025.
Scilex Holding (SCLX) Research & Development (2022 - 2026) Analysis & Trends
Scilex Holding's Research & Development history runs 5 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 30.7% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $21.5 million (up 138.78% YoY), while the FY2025 annual figure was $20.7 million, up 114.81% from the prior year.
- Research & Development for Q1 2026 stood at $3.2 million, down from $8.2 million in the prior quarter.
- The five-year high for Research & Development was $8.2 million in Q4 2025, with the low at $1.2 million in Q3 2022.
- The 5-year median for Research & Development is $2.7 million (2023), against an average of $3.3 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development slumped 42.31% in 2024, then soared 274.68% in 2025.
- Scilex Holding's Research & Development stood at $2.6 million in 2022, then climbed by 5.28% to $2.7 million in 2023, then slipped by 20.26% to $2.2 million in 2024, then jumped by 274.68% to $8.2 million in 2025, then plunged by 60.7% to $3.2 million in 2026.
- Business Quant data shows SCLX's Research & Development at $3.2 million in Q1 2026, $8.2 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 8.17 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 6.19 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.63 Mn |